Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Raphael J LandovitzDeborah DonnellMeredith E ClementBrett HanscomLeslie CottleLara CoelhoRobinson CabelloSuwat ChariyalertsakEileen F DunneIan FrankJorge A Gallardo-CartagenaAditya H GaurPedro GonzalesHa V TranJuan C HinojosaEsper G KallasColleen F KelleyMarcelo H LossoJ Valdez MadrugaKeren MiddelkoopNittaya PhanuphakBreno SantosOmar SuedJavier Valencia HuamaníEdgar T OvertonShobha SwaminathanCarlos Del RioRoy M GulickPaul RichardsonPhilip SullivanEstelle Piwowar-ManningMark MarzinkeCraig HendrixMaoji LiZhe WangJeanne MarrazzoEric DaarAida AsmelashTodd T BrownPeter AndersonSusan H EshlemanMarcus BryanCheryl BlanchetteJonathan LucasChristina PsarosSteven SafrenJeremy SugarmanHyman ScottJoseph J EronSheldon D FieldsNirupama D SistaKailazarid Gomez-FelicianoAndrea JenningsRyan M KofronTimothy H HoltzKatherine ShinJames F RooneyKimberly Y SmithWilliam SpreenDavid MargolisAlex RinehartAdeola AdeyeyeMyron S CohenMarybeth McCauleyBeatriz Grinsztejnnull nullPublished in: The New England journal of medicine (2021)
CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).